GemVax KAEL Reports Further Positive Data from GV1001 Phase ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SEOUL, Nov. 20, 2020, /PRNewswire-AsiaNet/-- GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association's Fall Conference from a Phase II trial in Alzheimer's disease ...
Authors: LATEST ASIANET NEWS RELEASES